16.43
0.03 (0.18%)
| 前收盘价格 | 16.40 |
| 收盘价格 | 16.44 |
| 成交量 | 1,886,424 |
| 平均成交量 (3个月) | 1,519,580 |
| 市值 | 830,475,584 |
| 价格/销量 (P/S) | 529.13 |
| 股市价格/股市净资产 (P/B) | 43.59 |
| 52周波幅 | |
| 利润日期 | 10 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -3.69 |
| 总债务/股东权益 (D/E MRQ) | 3.98% |
| 流动比率 (MRQ) | 10.44 |
| 营业现金流 (OCF TTM) | -127.65 M |
| 杠杆自由现金流 (LFCF TTM) | -72.82 M |
| 资产报酬率 (ROA TTM) | -58.15% |
| 股东权益报酬率 (ROE TTM) | -150.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | KalVista Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.40 |
|
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.47% |
| 机构持股比例 | 112.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2025 | 6,728,985 |
| Tang Capital Management Llc | 30 Sep 2025 | 5,041,798 |
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 5,039,867 |
| Suvretta Capital Management, Llc | 30 Sep 2025 | 4,768,712 |
| Parkman Healthcare Partners Llc | 30 Sep 2025 | 1,735,003 |
| Silverarc Capital Management, Llc | 30 Sep 2025 | 1,363,378 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 28.00 (Needham, 70.42%) | 购买 |
| 28.00 (Citizens, 70.42%) | 购买 | |
| 28.00 (JMP Securities, 70.42%) | 购买 | |
| 中 | 28.00 (70.42%) | |
| 平均值 | 28.00 (70.42%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 13.96 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 04 Dec 2025 | 28.00 (70.42%) | 购买 | 16.40 |
| 12 Sep 2025 | 28.00 (70.42%) | 购买 | 14.01 | |
| Citizens | 11 Nov 2025 | 28.00 (70.42%) | 购买 | 11.47 |
| JMP Securities | 12 Sep 2025 | 28.00 (70.42%) | 购买 | 14.01 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| AUDHYA PAUL K. | - | 13.36 | -5,296 | -70,755 |
| PALLEIKO BENJAMIN L | - | 13.36 | -10,940 | -146,158 |
| PIEKOS BRIAN | - | 13.36 | -4,471 | -59,733 |
| YEA CHRISTOPHER | - | 13.36 | -4,331 | -57,862 |
| 累积净数量 | -25,038 | |||
| 累积净值 ($) | -334,508 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 13.36 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| PALLEIKO BENJAMIN L | 职员 | 24 Nov 2025 | 卖 (-) | 10,940 | 13.36 | 146,158 |
| AUDHYA PAUL K. | 职员 | 24 Nov 2025 | 卖 (-) | 5,296 | 13.36 | 70,755 |
| YEA CHRISTOPHER | 职员 | 24 Nov 2025 | 卖 (-) | 4,331 | 13.36 | 57,862 |
| PIEKOS BRIAN | 职员 | 24 Nov 2025 | 卖 (-) | 4,471 | 13.36 | 59,733 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合